Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-01-23

Clinical Trial Update: Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects [Phase 2]

View source ↗

Summary

A Phase 2a study evaluating the combination of RDEA3170 and allopurinol in gout subjects has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Allopurinol (Allopurinol)
  • RDEA3170 (RDEA3170)

Snippet

Sponsor: Ardea Biosciences, Inc. | Conditions: Gout | Phase 2 | Status: COMPLETED | Results posted: 2018-01-23